鉴于科技投资的专业性、长期性、复杂性、风险性，一众民营创投公司发挥着市场化、专业化 的优势，发掘和培育了众多新质生产力的优秀企业、科技创新的独角兽企业。 会议指出，民间投资对稳就业稳经济具有重要作用。要聚焦企业关切的突出问题，在扩大准 入、打通堵点、强化保障等方面实施一批务实举措，进一步激发民间投资活力、促进民间投资 发展。要拓宽民间投资空间，支持民间资本加大新质生产力、新兴服务业、新型基础设施等领 域投资。要严格落实招标投标领域相关制度规定，保障中小企业政府采购预留份额，加大中央 预算内投资等对民间投资项目的支持力度。要营造公平竞争市场环境，破除限制民间投资的各 种隐性壁垒，加强创新支撑和融资支持，完善服务体系， 让民营企业敢投资、有回报 。 对于如何促进民间投资，近日，国家发展改革委政策研究室副主任、新闻发言人李超在国家发 展改革委例行发布会上表示，将抓紧研究出台促进民间投资发展的政策举措，完善民营企业参 与国家重大项目建设长效机制，对铁路、核电、油气管道等领域重大项目设定民间投资参股比 例的最低要求，支持更多符合条件的民间投资项目发行基础设施 REITs。 在股权投资行业，也有着一众民营企业 ——民营G ...

以下文章来源于LP波谱 ，作者王满华 LP波谱 . 本账号专注LP市场报道。"波浪、谱系"是识别市场的维度，也是定义市场的坐标；此外，波谱（Pop Art）也意为放低意义与史诗的执念，认同商业的日常之美。 将投中网设为"星标⭐"，第一时间收获最新推送 过去两年，包括黑石、KKR和贝莱德等在内的PE巨头都在扩大其在基础设施投资的业务规模和影响 力。 作者丨王满华 来源丨LP波谱 万亿PE巨头黑石，本周又传来重磅消息。 9月9日，黑石宣布，其最新基础设施二级份额基金Strategic Partners Infrastructure IV L.P.及相关承 诺计划基金的最终募资完成，总规模达55亿美元（约合人民币392亿元）。 据悉，该基金是目前全球规模最大的专注于基础设施领域的二级份额基金。 基础设施资产具有抗经济周期、现金流稳定、与通胀挂钩等特点，在全球经济不确定性增加的当下显 得尤为珍贵。根据麦肯锡数据预测，到2030年，全球基础设施资金缺口将高达57-67万亿美元。 过去两年，包括黑石、KKR和贝莱德等在内的PE巨头都在扩大其在基础设施投资的业务规模和影响 力。此次，黑石战略合作伙伴新基金创历史地募集到了5 ...

竞标方对星巴克中国的整体估值约为50亿美元，按照预计2025年4亿至5亿美元的EBITDA计算，对应估 值倍数在10倍左右。 从2024年底传出卖身消息后，星巴克的中国业务吸引了包括KKR、高瓴、PAG等国际顶级资本的参与 竞购，而市面上对于星巴克最终的买主和价格的传言始终不断。期间，甚至出现"反向管理层路演"的戏 剧性场面。 那么，为何是这四家投资机构闯进"决赛圈"？ Part01 决赛选手们 有过麦当劳中国投资经验的凯雷是四家PE中最意料之内的入选者。 2017年，麦当劳以20.8亿美元的价格出售了80%的麦当劳中国业务，凯雷在其中持有28%的股权。引入 凯雷等资方后，麦当劳中国发展迅速，一年就开了1000家店，为股东带来丰厚的回报。2023年，凯雷将 其所持28%的麦当劳中国股权以18亿美元的价格回售给麦当劳全球，净收益约12亿美元，实现约6.7倍 的投资回报。 竞购星巴克中国业务的名单缩短至四家：博裕资本、凯雷集团、EQT和红杉中国（HongShan）。 有消息称，这四家私募股权机构已于上周收到卖方发出的确认函。由高盛主导的此次出售预计将在10月 底前确定最终买家。若此次交易就此尘埃落定，持续一年，吸 ...

「 远非大结局。 」 文 ｜ 徐牧心 编辑 ｜ 陈之琰 竞购星巴克中国业务的名单缩短至四家：博裕资本、凯雷集团、EQT和红杉中国（HongShan）。 有消息称，这四家私募股权机构已于上周收到卖方发出的确认函。由高盛主导的此次出售预计将在10月底前确定最终买家。若此次交易就此尘埃落定，持续一 年，吸引十多家机构参与竞标的星巴克中国出售案终于将迎来一个结果。 竞标方对星巴克中国的整体估值约为50亿美元，按照预计2025年4亿至5亿美元的EBITDA计算，对应估值倍数在10倍左右。 从2024年底传出卖身消息后，星巴克的中国业务吸引了包括KKR、高瓴、PAG等国际顶级资本的参与竞购，而市面上对于星巴克最终的买主和价格的传言始终不 断。期间，甚至出现"反向管理层路演"的戏剧性场面。 那么，为何是这四家投资机构闯进"决赛圈"？ Part 01 决赛选手们 有过麦当劳中国投资经验的凯雷是四家PE中最意料之内的入选者。 2017年，麦当劳以20.8亿美元的价格出售了80%的麦当劳中国业务，凯雷在其中持有28%的股权。引入凯雷等资方后，麦当劳中国发展迅速，一年就开了1000家 店，为股东带来丰厚的回报。 2023年，凯雷将 ...

Group 1 - The company, Jiuding Investment, indicated on September 10 that investors should refer to its periodic reports for performance updates [1] - The company's private equity investment management business primarily targets leading enterprises and listed companies in advanced manufacturing, new consumption, and life health sectors within China [1]

Core Viewpoint - Tianjin Development (00882) announced a partnership agreement involving its indirect subsidiary, Lifespring Pharmaceutical (002393), to establish a fund with a total subscription amount of RMB 500 million (approximately HKD 547 million) [1] Group 1: Fund Structure and Investment Focus - The fund will primarily invest in equity of unlisted companies and/or stocks issued or traded in a non-public manner by listed companies, focusing on the health and biotechnology sectors in China, including innovative drugs, medical devices, and related services [1] - Lifespring Pharmaceutical has committed RMB 174 million (approximately HKD 190 million), representing 34.75% of the total subscription amount for the fund [1] Group 2: Risk Management and Investment Strategy - By participating in the fund, Lifespring Pharmaceutical's cost risk is limited to its subscribed amount, avoiding additional expenses and debts compared to direct investments [2] - The fund's investments require approval from the investment decision committee, ensuring that decisions are made with the consent of both Jianxin Equity and Taida Private Equity [2] Group 3: Strategic Benefits and Long-term Outlook - Participation in the fund will enhance the group's understanding of the latest industry developments, diversify investment risks, and identify potential strategic partners for future opportunities [3] - The investment is expected to provide opportunities for industry mergers and acquisitions aligned with the company's strategic development, improving capital allocation efficiency and enhancing sustainable operational capabilities [3]

Core Insights - The private equity and venture capital market in China saw a significant decline in new registrations, with only 5 new fund managers registered in August 2025, a drop of nearly 70% from July and a decrease of 64.3% compared to August 2024 [1] - Despite the drop in new fund managers, the total number of newly registered private equity and venture capital funds increased by 25.2% year-on-year, totaling 368 funds [1] - The primary equity investment market experienced 565 financing events, representing a year-on-year increase of 28.4% and a month-on-month increase of 2.4%, with a total disclosed financing amount of approximately 35.178 billion yuan, up 32.8% from August 2024 [1] Group 1: Fund Management and Investment Trends - Yida Capital, a management institution under Jiangsu High-tech Investment Group, has raised 5 new funds totaling 3.672 billion yuan as of August 2025 [2] - The newly established Nanjing Yida Xinsuo Equity Investment Partnership has a registered capital of 52 million yuan and includes notable investors such as Guangdong Junrui Industrial Co., Ltd. and Zhuhai Xinsuo United Investment Co., Ltd. [3] - Yida Capital reported 9 disclosed equity investment events, an 80% increase compared to August 2024, indicating a recovery in investment activity following a period of market tightening [3][5] Group 2: Investment Focus and Sector Distribution - Yida Capital is focusing on mid-stage growth projects, with over half of its investments in A-round companies, which are considered to have strong growth certainty and manageable risks [5] - More than two-thirds of Yida Capital's investments are concentrated in advanced manufacturing, with half of these projects in the integrated circuit sector, aligning with national priorities for "hard technology and industrial upgrading" [7] - Yida Capital's investment strategy emphasizes local opportunities, with approximately 55.6% of its investments registered in Jiangsu province, while also exploring opportunities in key regions such as Zhejiang, Shandong, Chongqing, and Shenzhen [9] Group 3: Notable Investment Cases - Pasini Perception Technology, specializing in tactile perception and embodied intelligence, completed a new round of Series A financing led by JD.com, with total financing reaching 1 billion yuan over four months [12] - The company has developed a high-precision multi-dimensional tactile sensor technology, addressing critical technology bottlenecks in China and enabling applications across various sectors including logistics, retail, and automotive manufacturing [12]

Group 1 - The number of newly registered private equity and venture capital fund managers in August 2025 dropped to 5, a decrease of nearly 70% compared to July, and a 64.3% decline year-on-year [1] - A total of 368 new private equity and venture capital funds were registered, showing a year-on-year growth of 25.2%, but a slight month-on-month decrease of 1.9% [1] - The domestic primary equity investment market recorded 565 financing events, with a year-on-year increase of 28.4% and a month-on-month increase of 2.4%, while the total disclosed financing amount reached approximately 35.178 billion yuan, up 32.8% year-on-year [1] Group 2 - Jin Yu Mao Wu, established in 2004, has a fund management scale exceeding 16 billion yuan and has invested in over 300 companies, with more than 30 successfully listed [3] - The company focuses on strategic emerging industries such as new materials, intelligent manufacturing, new energy, and health care [3] - As of the end of August 2025, Jin Yu Mao Wu registered 6 funds with a total registered capital of 2.666 billion yuan [3] Group 3 - The Suzhou Jin Yu Intelligent Venture Capital Partnership, with a total scale of 1 billion yuan, focuses on early, growth, and mature stage companies in emerging and frontier equipment fields [4] - Jin Yu Mao Wu's investment activity has shown a "structural surge under a stable tone," with a significant increase in investment events in the second half of 2024 and early 2025 [4][6] - The company primarily invests in growth stage projects, with 83.3% of investments in A and B rounds [6] Group 4 - Jin Yu Mao Wu's investment strategy aligns with the trends of "high-end, intelligent, and green" industrial upgrades, focusing on advanced manufacturing and enterprise services [8] - The company has a strong local presence in Jiangsu, which is beneficial for leveraging local resources and capturing quality companies [10] - Investments are also made in regions like Beijing, Hubei, and Shenzhen to diversify risks and enhance collaborative effects [10] Group 5 - Commer Pharmaceutical, a one-stop CDMO enterprise, completed a financing round of several million yuan, with funds aimed at business development and R&D platform construction [12] - Jin Yu Mao Wu participated in Commer's A round financing in 2022, and the current investment is through a city-level industrial fund managed by Jin Yu Mao Wu [12]

Core Insights - The company experienced significant growth in H1 2025, primarily due to a turnaround in investment income and revenue from the acquisition of Shenzhen JianYuan in the pharmaceutical sector [1][2]. Financial Performance - Adjusted revenue and net profit for H1 2025 were 665 million and 129 million yuan, respectively, reflecting year-on-year increases of 65% and 13% [2]. - Investment income, including investment gains and fair value changes, reached 36 million yuan, recovering from a negative 79 million yuan in the same period of 2024 [2]. - Private equity management fee income decreased by 5.07% to 210 million yuan, while revenue from the building materials segment grew by 4.88% to 274 million yuan [2]. - Revenue from the biopharmaceutical segment was 145 million yuan, driven by the acquisition of Shenzhen JianYuan, which contributed to both business and investment income growth [2]. Strategic Moves - The acquisition of Shenzhen JianYuan represents a deepened commitment to the biopharmaceutical industry, focusing on the research and sales of peptide products, which is expected to drive future revenue growth [3]. - The company is also looking to enhance its project portfolio by focusing on innovative technology sectors such as new industrialization and artificial intelligence [3]. Market Outlook - Recent improvements in the capital market are favorable for the company's project exits, which will accelerate the realization of returns from follow-on investments and performance compensation [3][4].

Investment Rating - The report assigns a rating of "Buy" for China Everbright Holdings (0165.HK) [7] Core Views - The report highlights that the company is entering a harvest period as it strategically invests in the technology innovation sector while experiencing a decline in funding costs [2] - The company is expected to see significant performance improvements due to the recovery of its fund management scale and the acceleration of IPOs in the capital market [11] Financial Summary - Total revenue is projected to increase from 1,660.87 million HKD in 2023 to 5,850.62 million HKD by 2027, reflecting a growth rate of 1411.61% in 2025 [5] - Net profit is expected to turn positive in 2025, reaching 2,044.37 million HKD, with a year-on-year growth of 207.09% [5] - The company's price-to-earnings (P/E) ratio is forecasted to improve from -4.65 in 2023 to 5.17 in 2027 [5] Investment Highlights - The company is a leader in the private equity industry, with a total estimated market value of 239 billion HKD and a target price of 14.18 HKD per share [11] - The firm has a diversified investment platform that includes private equity, venture capital, and fixed income funds, focusing on strategic emerging industries and technology innovation [16][24] - The management team has extensive experience in the financial industry, which supports the company's operational capabilities [25] Performance Improvement - The company has transitioned from losses to profitability, with a projected net profit of 3.99 million HKD in the first half of 2025, driven by successful investments in technology companies [26][31] - The fund management scale has rebounded, with a significant increase in seed fund ratios, indicating a strong recovery in investment performance [32][34] Strategic Focus - The company is focusing on technology innovation, with all new funds established since 2021 directed towards high-tech sectors [11][12] - The firm is expected to benefit from the increasing number of IPOs and improved market conditions, enhancing its exit channels for investments [50]